Marshall Davis

Marshall began his career at the University of Washington, focusing on gene regulatory networks in Mycobacterium tuberculosis and their responses to stress, particularly within the environments of macrophages and hypoxic granulomas. In 2022, he joined L-Seagen now L-Pfizer, to work on potency assay development. With his expertise in gene editing and cell line engineering, Marshall specializes in developing both cell-based and binding assays for release testing, contributing to the advancement of antibody-drug conjugates.